Analyst Research and Ratings: Trevena, Inc. (TRVN), Evolus, Inc. (EOLS)

Trevena, Inc. (NASDAQ:TRVN) tinted loss of -5.7% (-0.09 points) to US$1.49. The volume of 3.51 Million shares climbed up over an trading activity of 3.27 Million shares. EPS ratio determined by looking at last 12 month figures is -0.57. Over the same time span, the stock marked US$3.58 as its best level and the lowest price reached was US$0.38. The corporation has a market cap of US$145.9 Million.

Trevena, Inc. (NASDAQ:TRVN)’s earnings per share has been growing at a -11.1 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at -94.8 percent while most common profitability ratio return on investment (ROI) was 0 percent. The company’s institutional ownership is monitored at 38.3 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 0 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 1 think it is Hold. Recently, analysts have updated the overall rating to 2.5. 1 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

Evolus, Inc. (NASDAQ:EOLS) is worth US$784.05 Million and has recently fallen -2.11% to US$26. The latest exchange of 1.49 Million shares is below its average trading activity of 866.43 Million shares. The day began at US$0 but the price moved to US$0 at one point during the trading and finally capitulating to a session high of US$0. The stock tapped a 52-week high of US$39.5 while the mean 12-month price target for the shares is US$29.8.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 6.93, and a price to sales ratio of 0. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown 0%. With an institutional ownership near 25.3%, it carries an earnings per share ratio of -1.11.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 1 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 4 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.8.